Bharat Biotech has submitted Phase III trial data for the Covaxin coronavirus vaccine to the DCGI (Drug Controller General of India).
The drug regulator's SEC (subject expert committee) is expected to meet around noon to discuss the results. The data has not yet been fully published in a recognised, peer-reviewed journal.
